UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2185-7
Program Prior Authorization – Medical Necessity
Medication Slynd® (drospirenone)
P&T Approval Date 1/2020, 7/2020, 4/2021, 1/2022, 2/2023, 2/2024, 9/2024
Effective Date 11/17/2024
1. Background:
Oral contraceptives are available as either combination estrogen/progesterone-containing
contraceptives or as progesterone-only contraceptives. Progesterone-only contraceptives should
be used when estrogen-containing contraceptives are contraindicated. Slynd (drospirenone) is a
progesterone-only contraceptive indicated for use by females of reproductive potential to
prevent pregnancy.
2. Coverage Criteriaa:
A. Authorization
1. Slynd will be approved based on all of the following criteria:
a. Used for the prevention of pregnancy
-AND-
b. History of failure, contraindication, or intolerance to both of the following
progesterone-only contraceptives
1) norethindrone (generic Ortho Micronor®)
2) norgestrel (Opill)
-AND-
c. Provider attests that patient has been instructed to avoid estrogen containing
contraceptives due to a health concern or the patient is currently breastfeeding
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic
class.
4. References:
1. Slynd [package insert]. Florham Park, NJ: Exeltis USA, Inc; May 2019.
2. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for
Contraceptive Use, 2016. MMWR Recomm Rep 2016;65(No. RR-4):1–66. DOI:
http://dx.doi.org/10.15585/mmwr.rr6504a1
Program Prior Authorization – Medical Necessity
Change Control
1/2020 New program.
7/2020 Updated contraindications to include history of breast cancer and
migraine with aura.
4/2021 Simplified contraindication language and added documentation of
contraindication.
1/2022 Annual review. No changes.
2/2023 Annual review. No changes.
2/2024 Annual review. Updated criteria to note a progesterone-only
contraceptive due to the approval of the over-the-counter contraceptive.
9/2024 Require failure of two progestin only contraceptives, removed estrogen
failure and updated prescriber attestation statement. Reauthorization
removed.
© 2024 UnitedHealthcare Services, Inc.
2